Pharmaceutical care for a patient with visual abnormalities induced by oxaliplatin by clinical pharmacists
- VernacularTitle:临床药师对奥沙利铂致视觉异常患者的药学监护
- Author:
Yang ZHANG
1
;
Shuhe CHEN
1
;
Yue GAO
2
Author Information
1. Dept. of Pharmacy，Hubei Provincial Hospital of TCM，Wuhan 430061，China;Dept. of Pharmacy，the Affiliated Hospital of Hubei University of Chinese Medicine，Wuhan 430061，China;Hubei Academy of Traditional Chinese Medicine，Wuhan 430074，China
2. Dept. of Pharmacy，Hubei Provincial Hospital of TCM，Wuhan 430061，China;Dept. of Pharmacy，the Affiliated Hospital of Hubei University of Chinese Medicine，Wuhan 430061，China
- Publication Type:Journal Article
- Keywords:
oxaliplatin;
adverse drug reactions;
visual abnormalities;
clinical pharmacist;
pharmaceutical care
- From:
China Pharmacy
2025;36(20):2577-2581
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To report a case of visual abnormalities induced by oxaliplatin， and provide a reference for clinical medication safety. METHODS Clinical pharmacists conducted the pharmaceutical care for a colon cancer patient who developed visual abnormalities during treatment with oxaliplatin. After the patient experienced two episodes of visual abnormalities in the first chemotherapy cycle， the pharmacists recommended suspending oxaliplatin and reducing its dose in the next cycle. When visual symptoms persisted in the second cycle， they recommended permanent discontinuation of oxaliplatin. Concurrently， they provided medication education to the patient and family. Using Naranjo’s Adverse Drug Reaction Probability Scale， the pharmacists assessed the correlation between oxaliplatin and the visual abnormalities， and analyzed the characteristics of this adverse reaction. RESULTS & CONCLUSIONS The physician adopted the clinical pharmacists’ recommendations. After discontinuation of the drug， the patient’s vision gradually returned to normal. The correlation between oxaliplatin and visual abnormalities was assessed as “probable”. Oxaliplatin-induced visual abnormalities are relatively rare and often occur within the first three cycles of treatment. Most patients recover their vision within two weeks after discontinuation， while a small number may progress to permanent visual impairment. Clinical pharmacist ensured the patient’s medication safety by evaluating the correlation between oxaliplatin and visual abnormalities， adjusting medication regimens， providing pharmaceutical care and medication education， and providing other pharmaceutical services.
